These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 20814894)

  • 41. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study.
    Sanyal A; Younossi ZM; Bass NM; Mullen KD; Poordad F; Brown RS; Vemuru RP; Mazen Jamal M; Huang S; Merchant K; Bortey E; Forbes WP
    Aliment Pharmacol Ther; 2011 Oct; 34(8):853-61. PubMed ID: 21848797
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rifaximin may have a dramatic effect on hepatic encephalopathy.
    Lamb C; Reddy AV
    Clin Med (Lond); 2012 Oct; 12(5):489-90. PubMed ID: 23101155
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rifaximin is an efficacious treatment for the Parkinsonian phenotype of hepatic encephalopathy.
    Kok B; Foxton MR; Clough C; Shawcross DL
    Hepatology; 2013 Oct; 58(4):1516-7. PubMed ID: 23471844
    [No Abstract]   [Full Text] [Related]  

  • 44. [Rifaximin for hepatic encephalopathy in children. Case report].
    Malla I; Torres Cerino V; Villa A; Cheang Y; Giacove G; Pedreira A; Silva M
    Arch Argent Pediatr; 2011 Dec; 109(6):e113-5. PubMed ID: 22231877
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria.
    Gillis JC; Brogden RN
    Drugs; 1995 Mar; 49(3):467-84. PubMed ID: 7774516
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ammonia abolishers: antibiotics for hepatic encephalopathy.
    Felicilda-Reynaldo RF
    Medsurg Nurs; 2012; 21(3):173-5; quiz 176. PubMed ID: 22866441
    [No Abstract]   [Full Text] [Related]  

  • 47. Hepatic encephalopathy: pathophysiology and emerging therapies.
    Sundaram V; Shaikh OS
    Med Clin North Am; 2009 Jul; 93(4):819-36, vii. PubMed ID: 19577116
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rifaximin therapy in minimal hepatic encephalopathy cirrhotics.
    Zullo A; Hassan C; Lorenzetti R
    Am J Gastroenterol; 2011 Nov; 106(11):2041; author reply 2041-2. PubMed ID: 22056578
    [No Abstract]   [Full Text] [Related]  

  • 49. Update on management of patients with overt hepatic encephalopathy.
    Chacko KR; Sigal SH
    Hosp Pract (1995); 2013 Aug; 41(3):48-59. PubMed ID: 23948621
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Letter: the effects of rifaximin in hepatic encephalopathy.
    Dai C; Jiang M; Sun MJ
    Aliment Pharmacol Ther; 2014 Oct; 40(7):857-8. PubMed ID: 25185736
    [No Abstract]   [Full Text] [Related]  

  • 51. Lactulose for hepatic encephalopathy.
    Med Lett Drugs Ther; 1976 Jan; 18(1):3-4. PubMed ID: 1105127
    [No Abstract]   [Full Text] [Related]  

  • 52. Letter: the effects of rifaximin in hepatic encephalopathy--authors' reply.
    Kimer N; Krag A; Gluud LL
    Aliment Pharmacol Ther; 2014 Oct; 40(7):858-9. PubMed ID: 25185737
    [No Abstract]   [Full Text] [Related]  

  • 53. Persistent portosystemic shunts after liver transplantation causing episodic hepatic encephalopathy.
    Barritt AS; Fried MW; Hayashi PH
    Dig Dis Sci; 2010 Jun; 55(6):1794-8. PubMed ID: 19655248
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Editorial: prolonged remission from hepatic encephalopathy with rifaximin.
    Orr JG; Hudson M
    Aliment Pharmacol Ther; 2015 Jan; 41(2):228. PubMed ID: 25511766
    [No Abstract]   [Full Text] [Related]  

  • 55. Comparison of results of long-term treatment of chronic hepatic encephalopathy with lactulose and sorbitol.
    Rodgers JB; Kiley JE; Balint JA
    Am J Gastroenterol; 1973 Nov; 60(5):459-65. PubMed ID: 4587191
    [No Abstract]   [Full Text] [Related]  

  • 56. Quality of life as a therapeutic objective in the management of hepatic encephalopathy and the potential role of rifaximin-α.
    Deltenre P; Labenz C; Schuchmann M
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e1032-e1038. PubMed ID: 34402475
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis.
    Prakash RK; Kanna S; Mullen KD
    Clin Ther; 2013 Sep; 35(9):1458-73. PubMed ID: 23972578
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of rifaximin use for hepatic encephalopathy on the risk of early post-transplant infections in liver transplant recipients.
    Sun HY; Wagener M; Cacciarelli TV; Singh N
    Clin Transplant; 2012; 26(6):849-52. PubMed ID: 22432742
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A non-absorbable rifamycin for treatment of hepatic encephalopathy.
    Testa R; Eftimiadi C; Sukkar GS; De Leo C; Rovida S; Schito GC; Celle G
    Drugs Exp Clin Res; 1985; 11(6):387-92. PubMed ID: 3836135
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rifaximine versus neomycin in the treatment of portosystemic encephalopathy.
    Di Piazza S; Gabriella Filippazzo M; Valenza LM; Morello S; Pastore L; Conti A; Cottone S; Pagliaro L
    Ital J Gastroenterol; 1991; 23(7):403-7. PubMed ID: 1742538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.